Fieldview Capital Management LLC Acquires Shares of 1,081 United Therapeutics Corporation $UTHR

Fieldview Capital Management LLC acquired a new stake in United Therapeutics Corporation (NASDAQ:UTHR) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 1,081 shares of the biotechnology company’s stock, valued at approximately $527,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Leuthold Group LLC increased its holdings in shares of United Therapeutics by 41.4% in the fourth quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock valued at $5,200,000 after purchasing an additional 3,126 shares during the period. Tobam increased its holdings in shares of United Therapeutics by 183.9% in the third quarter. Tobam now owns 7,646 shares of the biotechnology company’s stock valued at $3,205,000 after purchasing an additional 4,953 shares during the period. UBS Group AG increased its holdings in shares of United Therapeutics by 45.3% in the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock valued at $110,045,000 after purchasing an additional 70,445 shares during the period. Perpetual Ltd acquired a new position in shares of United Therapeutics in the fourth quarter valued at approximately $1,059,000. Finally, Brookstone Capital Management increased its holdings in shares of United Therapeutics by 25.4% in the fourth quarter. Brookstone Capital Management now owns 6,622 shares of the biotechnology company’s stock valued at $3,227,000 after purchasing an additional 1,342 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Price Performance

Shares of UTHR stock opened at $549.57 on Tuesday. The business’s fifty day moving average price is $566.45 and its 200 day moving average price is $522.10. United Therapeutics Corporation has a 1-year low of $272.12 and a 1-year high of $609.35. The firm has a market capitalization of $23.33 billion, a PE ratio of 20.29, a P/E/G ratio of 1.78 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The business had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same period in the prior year, the company earned $6.63 EPS. The company’s revenue was down 1.6% on a year-over-year basis. Equities research analysts expect that United Therapeutics Corporation will post 26.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on UTHR shares. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $575.00 to $735.00 in a report on Thursday, May 7th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Cantor Fitzgerald boosted their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. HC Wainwright boosted their target price on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a report on Tuesday, March 31st. Finally, UBS Group boosted their target price on United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a report on Thursday, March 5th. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $619.42.

Insiders Place Their Bets

In related news, CFO James Edgemond sold 10,000 shares of the company’s stock in a transaction on Monday, March 23rd. The stock was sold at an average price of $527.48, for a total transaction of $5,274,800.00. Following the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at $9,956,712.48. This represents a 34.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 634,468 shares of company stock worth $357,970,302 over the last quarter. Corporate insiders own 8.60% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.